PRESS RELEASE : B.R.A.I.N. Biotechnology Research And Information Network AG: Roquette and BRAIN Group agree on production scale-up for protein sweetener

DGAP-News: B.R.A.I.N. Biotechnology Research And Information Network AG / Key word(s): Agreement 
B.R.A.I.N. Biotechnology Research And Information Network AG: Roquette and BRAIN Group agree on production scale-up for 
protein sweetener 
2021-01-13 / 08:00 
The issuer is solely responsible for the content of this announcement. 
=---------------------------------------------------------------------------------------------------------------------- 
Lestrem and Zwingenberg, 13^th January 2021 
Roquette and BRAIN Group agree on production scale-up for protein sweetener 
Roquette, a global leader in plant-based ingredients for food, nutrition and health markets, biotech pioneer BRAIN AG, 
and BRAIN Group company AnalytiCon Discovery have successfully completed the R&D phase for the development of Brazzein. 
The partners have now signed a contractual agreement for its approval and production. 
Brazzein is a protein sweetener which is naturally found in African berries Pentadiplandra brazzeana Baillon. This high 
intensive sweetener provides an outstanding sweetening potency still preserving taste profile and sugar free 
functionality. As part of their newly agreed Joint Development Agreement (JDA), Roquette and BRAIN, will now progress 
with the approval and industrial scale-up of the protein sweetener in the food and beverage sector. Roquette and BRAIN, 
who first came together during the DOLCE research program and subsequently decided to further develop this sweetener by 
fermentation, see very good commercial opportunities for this compound, primarily in the beverage industry. 
In preparation for the upcoming production phase, BRAIN has already established a highly potent GRAS (Generally 
Recognized As Safe) microorganism for the biotechnological production of the sweetener. GRAS strains are well suited 
for the approval for the food and beverage sector, and BRAIN has already produced the sweetener at laboratory scale 
with commercially viable yields. 
Dr. Sergio Neves, Head of Nutrition & Health, R&D at Roquette emphasizes: "Having completed the DOLCE R&D program, we 
are now looking to upscale production, and expect to bring the protein sweetener to the market within the next three to 
four years. Several top Food & Beverage companies have already shown great interest and aim to support us in this 
project." 
Adriaan Moelker, CEO BRAIN AG, comments: "We are very pleased with the positive feedback from Roquette and various 
consumer goods manufacturers. The sweetener, which we are now jointly approving and producing, was developed especially 
for the beverage industry, which today utilizes approximately 70% of the sugar consumed worldwide in its products. This 
illustrates the sales potential that this novel sweetener offers. In the fast growing sweetener market, where taste 
profile and nutrition have to be enhanced in parallel, we expect our new product to strongly meet the increasing 
consumer demand." 
About Roquette: "Offering the best of nature" 
Roquette is a global leader in plant-based ingredients, a pioneer of plant proteins and a leading provider of 
pharmaceutical excipients. In collaboration with its customers and partners, the group addresses current and future 
societal challenges by unlocking the potential of nature to offer the best ingredients for food, nutrition and health 
markets. These ingredients respond to unique and essential needs, enable healthier lifestyles and are critical 
components of life-saving medicines. 
Thanks to a constant drive for innovation and a long-term vision, the group is committed to improving the well-being of 
millions of people all over the world while taking care of resources and territories. 
Roquette currently operates in over 100 countries, has a turnover of around EUR 3.7 billion and employs 8,670 people 
worldwide. 
About BRAIN 
B.R.A.I.N. Biotechnology Research and Information Network AG (BRAIN AG; ISIN DE0005203947 / WKN 520394) is one of 
Europe's leading technology companies in the area of industrial biotechnology, the core discipline of the bioeconomy. 
As such, BRAIN identifies previously untapped efficient enzymes, microbial producer organisms and natural substances 
from complex biological systems, in order to make them utilizable in an industrial context. The innovative solutions 
and products developed by means of "Nature's Toolbox" are successfully applied in the chemicals, cosmetics and food 
industries. 
BRAIN's business model stands on on two pillars. The BioScience segment comprises mainly research and development 
business with industrial partners, and the company's own research and development. The BioIndustrial segment consists 
mainly of business with industrially scalable products. As part of a growth-oriented industrialization strategy, in 
February 2016 BRAIN AG became the first bioeconomy company to be listed on the Prime Standard of the Frankfurt Stock 
Exchange. 
Disclaimer 
This press release contains forward-looking statements. These statements reflect the current views, expectations, and 
assumptions of the management of BRAIN AG, and are based on information currently available to the management. 
Forward-looking statements are no guarantees of future performance, and entail both known and unknown risks as well as 
uncertainties that could cause actual results, performance or events to differ materially from those expressed or 
implied in such statements. Numerous factors exist that could influence the future performance by, and future 
developments at, BRAIN AG and the BRAIN Group. Such factors include, but are not limited to, changes in the general 
economic and competitive environment, risks associated with capital markets, currency exchange rate fluctuations, 
changes in international and national laws and regulations, in particular with respect to tax laws and regulations, as 
well as other factors. BRAIN AG does not undertake any obligation to update or revise any forward-looking statements. 
Media Contact Roquette 
Carole Petitjean 
Corporate Communications 
[e-mail] 
www.roquette.com 
Contact Investor Relations BRAIN AG 
Michael Schneiders 
Head of Investor Relations 
Phone: [phone] 
Email: [e-mail] 
Media Contact BRAIN AG 
Dr. Stephanie Konle 
PR & Corporate Communications 
Phone: [phone] 
Email: [e-mail] 
 
=---------------------------------------------------------------------------------------------------------------------- 
2021-01-13 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. 
The issuer is solely responsible for the content of this announcement. 
The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. 
Archive at www.dgap.de 
=---------------------------------------------------------------------------------------------------------------------- 
Language:     English 
Company:      B.R.A.I.N. Biotechnology Research And Information Network AG 
              Darmstädter Straße 34-36 
              64673 Zwingenberg 
              Germany 
Phone:        [phone] / 9331-0 
Fax:          [phone] / 9331-11 
E-mail:       [e-mail] 
Internet:     www.brain-biotech.com 
ISIN:         DE0005203947 
WKN:          520394 
Listed:       Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, 
              Hamburg, Munich, Stuttgart, Tradegate Exchange 
EQS News ID:  1160158 
 
End of News   DGAP News Service 
=---------- 

(MORE TO FOLLOW) Dow Jones Newswires

January 13, 2021 02:01 ET (07:01 GMT)